Computer-aided retrometabolic drug design: Soft drugs

Expert Opinion on Drug Discovery

Volumn 2, Issue 7, 2007, Pages 923-933

  Buchwald, Peter ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Antedrug; Carboxylesterase; Metabolism; Prodrug; QSAR

Indexed keywords

ACICLOVIR; ALENDRONIC ACID; AMIODARONE; ATENOLOL; BREVIBLOCK; CHLOROBENZILATE; CLEVIDIPINE; CROMOGLYCATE DISODIUM; CYCLOSPORIN A DERIVATIVE; DEXANABINOL; ENALAPRIL; ENALAPRILAT; ESMOLOL; ESTRADIOL DERIVATIVE; ETIPREDNOL DICLOACETATE; FENTANYL; FLESTOLOL; FLUOCORTIN BUTYL; GAMMA LACTONE DERIVATIVE; IRINOTECAN; LANDIOLOL; LISINOPRIL; LOTEPREDNOL ETABONATE; LOTEPREDNOL ETABONATE PLUS TOBRAMYCIN; METOPROLOL; MEVINOLIN; OMEPRAZOLE; REMIFENTANIL; SIMVASTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XIMELAGATRAN;

COMPUTER MODEL; COMPUTER PREDICTION; COMPUTER PROGRAM; COMPUTER SIMULATION; DRUG DESIGN; DRUG METABOLISM; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; HYDROLYSIS; HYDROPHILICITY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

EID: 34547487835     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.7.923     Document Type: Review

References (92)

1. RUFFOLO RR: Why has R&D productivity declined in the pharmaceutical industry? Expert Opin. Drug Discov. (2006) 1(2):99-102.
2. BLEICHER KH, BÖHM HJ, MÜLLER K, ALANINE AI: Hit and lead generation: beyond high-throughput screening. Nat. Rev. Drug Discov. (2003) 2(5):369-378.
3. OVERINGTON JP, AL-LAZIKANI B, HOPKINS AL: How many drug targets are there? Nat. Rev. Drug Discov. (2006) 5(12):993-996.
4. PROUDFOOT JR: Drugs, leads, and drug-likeness: an analysis of some recently launched drugs. Bioorg. Med. Chem. Lett. (2002) 12:1647-1650.
5. LIPINSKI C, HOPKINS A: Navigating chemical space for biology and medicine. Nature (2004) 432(7019):855-861.
6. BODOR N: Drug targeting and retrometabolic drug design approaches. Adv. Drug Deliv. Rev. (1994) 14:157-166.
7. BODOR N, BUCHWALD P: Drug targeting via retrometabolic approaches. Pharmacol. Ther. (1997) 76:1-27.
8. BODOR N, BUCHWALD P: Retrometabolism-based drug design and targeting: In: Burger's Medicinal Chemistry and Drug Discovery Volume 2, Drug Discovery and Drug Development, 6th edn. Abraham DJ (Ed.), Wiley, New York (2003):533-608.
9. BODOR N, FARAG HH, BREWSTER ME: Site-specific, sustained release of drugs to the brain. Science (1981) 214:1370-1372.
10. BODOR N: Redox drug delivery systems for targeting drugs to the brain. Ann. NY Acad. Sci. (1987) 507:289-306.
11. BODOR N, PROKAI L: Site- and stereospecific ocular drug delivery by sequential enzymatic bioactivation. Pharm. Res. (1990) 7:723-725.
12. BODOR N, BUCHWALD P: Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv. Drug Deliv. Rev. (1999) 36:229-254.
13. BODOR N: Designing safer drugs based on the soft drug approach. Trends Pharmacol. Sci. (1982) 3:53-56.
14. BODOR N: Novel approaches to the design of safer drugs: soft drugs and site-specific chemical delivery systems. Adv. Drug Res. (1984) 13:255-331.
15. BODOR N: Soft drugs: principles and methods for the design of safe drugs. Med. Res. Rev. (1984) 3:449-469.
16. BODOR N, BUCHWALD P: Soft drug design: general principles and recent applications. Med. Res. Rev. (2000) 20:58-101.
17. LIN JH, LU AY: Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol. Rev. (1997) 49:403-449.
18. LEE HJ, SOLIMAN MRI: Anti-inflammatory steroids without pituitary-adrenal suppresion. Science (1982) 215:989-991.
19. PROCOPIOU PA, BIGGADIKE K, ENGLISH AF et al.: Novel glucocorticoid antedrugs possessing a 17β-(γ-lactone) ring. J. Med. Chem. (2001) 44:602-612.
20. LEE HJ, COOPERWOOD JS, YOU Z, KO DH: Prodrug and antedrug: two diametrical approaches in designing safer drugs. Arch. Pharm. Res. (2002) 25:111-136.
21. SAWA M, TSUKAMOTO T, KIYOI T et al.: New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs. J. Med. Chem. (2002) 45:930-936.
22. SHIMIZU K, KAWASE A, HANEISHI T et al.: Novel vitamin D3 antipsoriatic antedrugs: 16-en-22-oxa-1α,25-(OH)2D3 analogs. Bioorg. Med. Chem. Lett. (2006) 14(6):1838-1850.
23. SHIMIZU K, KAWASE A, HANEISHI T et al.: Design and evaluation of new antipsoriatic antedrug candidates having 16-en-22-oxa-vitamin D3 structures. Bioorg. Med. Chem. Lett. (2006) 16(12):3323-3329.
24. WILLIAMS JA, HYLAND R, JONES BC et al.: Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos. (2004) 32(11):1201-1208.
25. WIENKERS LC, HEATH TG: Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Discov. (2005) 4(10):825-833.
26. WERMUTH CG: Specific substituent effects. In: The Practice of Medicinal Chemistry. Wermuth CG (Ed.), Academic Press, London (1996):311-344.
27. LEINWEBER F-J: Possible physiological roles of carboxylic ester hydrolases. Drug Metab. Rev. (1987) 18:379-439.
28. OAKESHOTT JG, CLAUDIANOS C, RUSSELL RJ, ROBIN GC: Carboxyl/ cholinesterases: a case study of the evolution of a successful multigene family. Bioessays (1999) 21:1031-1042.
29. SATOH T, HOSOKAWA M: The mammalian carboxylesterases: from molecules to functions. Annu. Rev. Pharmacol. Toxicol. (1998) 38:257-288.
30. SATOH T, HOSOKAWA M: Structure, function and regulation of carboxylesterases. Chem. Biol. Interact. (2006) 162(3):195-211.
31. SATOH T, TAYLOR P, BOSRON WF et al.: Current progress on esterases: from molecular structure to function. Drug Metab. Dispos. (2002) 30(5):488-493.
32. IMAI T, TAKETANI M, SHII M, HOSOKAWA M, CHIBA K: Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine. Drug Metab. Dispos. (2006) 34(10):1734-1741.
33. BUCHWALD P: Structure-metabolism relationships: steric effects and the enzymatic hydrolysis of carboxylic esters. Min. Rev. Med. Chem. (2001) 1:101-111.
34. BUCHWALD P, BODOR N: Physicochemical aspects of the enzymatic hydrolysis of carboxylic esters. Pharmazie (2002) 57:87-93.
35. COOK CS, KARABATSOS PJ, SCHOENHARD GL, KARIM A: Species dependent esterase activities for hydrolysis of an anti-HIV prodrug glycovir and bioavalability of active SC-48334. Pharm. Res. (1995) 12:1158-1164.
36. JOHNSON SCD: The role of simulation in the management of research: what can the pharmaceutical industry learn from the aerospace industry? Drug Infect. J. (1998) 32:961-969.
37. BUCHWALD P: A general bilinear model to describe growth or decline time-profiles. Math. Biosci. (2007) 205(1):108-136.
38. CHENG AC, COLEMAN RG, SMYTH KT et al.: Structure-based maximal affinity model predicts small-molecule druggability. Nat. Biotechnol. (2007) 25(1):71-75.
39. AGORAM B, WOLTOSZ WS, BOLGER MB: Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv. Drug Deliv. Rev. (2001) 50(Suppl. 1):S41-S67.
40. POULIN P, THEIL F-P: Prediction of pharmacokinetics prior to in vivo studies. II. Genetic physiologically based pharmacokinetic models of drug disposition. J. Pharm. Sci. (2002) 91:1358-1370.
41. MEIBOHM B, DERENDORF H: Basic concepts of pharmacokinetic/ pharmacodynamic (PK/PD) modelling. Int. J. Clin. Pharmacol. Ther. (1997) 35:401-413.
42. MEIBOHM B, DERENDORF H: Pharmacokinetic/pharmacodynamic studies in drug product development. J. Pharm. Sci. (2002) 91:18-31.
43. ROONEY KF, SNOECK E, WATSON PH: Modeling and simulation in clinical drug development. Drug Discov. Today (2001) 6:802-806.
44. SCHNEIDER G, FECHNER U: Computer-based de novo design of drug-like molecules. Nat. Rev. Drug Discov. (2005) 4(8):649-663.
45. VAN DE WATERBEEMD H, GIFFORD E: ADMET in silico modelling:. towards prediction paradise? Nat. Rev. Drug Discov. (2003) 2:192-204.
46. BENDER A, GLEN RC: A discussion of measures of enrichment in virtual screening: comparing the information content of descriptors with increasing levels of sophistication. J. Chem. Inf. Model (2005) 45(5):1369-1375.
47. WARREN GL, ANDREWS CW, CAPELLI AM et al.: A critical assessment of docking programs and scoring functions. J. Med. Chem. (2006) 49(20):5912-5931.
48. KUBINYI H: Chance favors the prepared mind - from serendipity to rational drug design. J. Recept. Signal Transduct. Res. (1999) 19(1-4):15-39.
49. BODOR N, BUCHWALD P, HUANG M-J: The role of computational techniques in retrometabolic drug design strategies. In: Computational Molecular Biology. Leszczyuski J (Ed.), Elsevier, Amsterdam (1999):569-618.
50. BUCHWALD P, BODOR N: Structure-based estimation of enzymatic hydrolysis rates and its application in computer-aided retrometabolic drug design. Pharmazie (2000) 55:210-217.
51. POP E, BUCHWALD P: Attempts of ranking in a series of synthetic nonpsychotropic cannabinoids. SAR QSAR Environ. Res. (2001) 12:113-127.
52. BODOR N, GABANYI Z, WONG C-K: A new method for the estimation of partition coefficient. J. Am. Chem. Soc. (1989) 111:3783-3786.
53. BODOR N, HUANG M-J: A new method for the estimation of the aqueous solubility of organic compounds. J. Pharm. Sci. (1992) 81:954-960.
54. BODOR N, BUCHWALD P: Molecular size based approach to estimate partition properties for organic solutes. J. Phys. Chem. B (1997) 101:3404-3412.
55. BUCHWALD P, BODOR N: Octanol-water partition of nonzwitterionic peptides: predictive power of a molecular size-based model. Proteins (1998) 30:86-99.
56. BUCHWALD P, BODOR N: Quantitative structure-metabolism relationships: steric and nonsteric effects in the enzymatic hydrolysis of noncongener carboxylic esters. J. Med. Chem. (1999) 42:5160-5168.
57. BUCHWALD P, BODOR N: Simple model for nonassociative organic liquids and water. J. Am. Chem. Soc. (2000) 122:10671-10679.
58. BUCHWALD P, BODOR N: Computer-aided drug design: the role of quantitative structure-property, structure-activity, and structure-metabolism relationships (QSPR, QSAR, QSMR). Drugs Future (2002) 27:577-588.
59. BODOR N, BUCHWALD P., HUANG M-J: Computer-assisted design of new drugs based on retrometabolic concepts. SAR QSAR Environ. Res. (1998) 8:41-92.
60. DEWAR MJS, ZOEBISCH EG, HEALY EF, STEWART JJP: AM1: a new general purpose quantum mechanical molecular model. J. Am. Chem. Soc. (1985) 107:3902-3909.
61. BENDER A, GLEN RC: Molecular similarity: a key technique in molecular informatics. Org. Biomol. Chem. (2004) 2(22):3204-3218.
62. WILLETT P: Similarity-based virtual screening using 2D fingerprints. Drug Discov. Today (2006) 11(23-24):1046-1053.
63. BRÜSTLE M, BECK B, SCHINDLER T et al.: Descriptors, physical properties, and drug-likeness. J. Med. Chem. (2002) 45:3345-3355.
64. BUCHWALD P, BODOR N: Octanol-water partition: searching for predictive models. Curr. Med. Chem. (1998) 5:353-380.
65. BODOR N, OSHIRO Y, LOFTSSON T, KATOVICH M, CALDWELL W: Soft drugs. 6. The application of the inactive metabolite approach for design of soft β-blockers. Pharm. Res. (1984) 3:120-125.
66. BODOR N, EL-KOUSSI A, KANO M, KHALIFA MM: Soft drugs. 7. β-Blockers for systemic and ophthalmic use. J. Med. Chem. (1988) 31:1651-1656.
67. BODOR N, BUCHWALD P: Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J. (2005) 7(4):article 79 (E820-E833).
68. ERHARDT PW, WOO CM, ANDERSON WG, GORCZYNSKI RJ: Ultra-short-acting β-adrenergic receptor blocking agents. 2. (Arlyoxy)propanolamines containing esters on the aryl function. J. Med. Chem. (1982) 25:1408-1412.
69. IGUCHI S, IWAMURA H, NISHIZAKI M et al.: Development of a highly cardioselective ultra short-acting β-blocker, ONO-1101. Chem. Pharm. Bull. (1992) 40:1462-1469.
70. KITAMURA A, SAKAMOTO A, INOUE T, OGAWA R: Efficacy of an ultrashort-acting β-adrenoreceptor blocker (ONO-1101) in attenuating cardiovascular responses to endotracheal intubation. Eur. J. Clin. Pharmacol. (1997) 51:467-471.
71. HAMMER RH, AMIN K, GUNES ZE, BROUILLETTE G, BODOR N: Novel soft anticholinergic agents. Drug Des. Deliv. (1988) 2:207-219.
72. BUCHWALD P, BODOR N: Soft quaternary anticholinergies: comprehensive QSAR with a lineatized biexponential (LinBiExp) model. J. Med. Chem. (2006) 49(3):883-891.
73. FELDMAN PL, JAMES MK, BRACKEEN MF et al.: Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgetics. J. Med. Chem. (1991) 34:2202-2208.
74. JAMES MK, FELDMAN PL., SCHUSTER SV et al.: Opioid receptor activity of GI 87084B, a novel ultra-short acting analgesic, in isolated tissues. J. Pharmacol. Exp. Ther. (1991) 259:712-718.
75. SNEYD JR: Recent advances in intravenous anaesthesia. Br. J. Anaesth. (2004) 93(5):725-736.
76. BODOR N, BUCHWALD P: Corticosteroid design for the treatment of asthma: structural insights and the therapeutic potential of soft corticosteroids. Curr. Pharm. Des. (2006) 12(25):3241-3260.
77. KURUCZ I, TÓTH S, NÉMETH K et al.: Potency and specificity of the pharmacological action of a new, antiasthmatic, topically administered soft steroid, etiprednol dicloacetate (BNP-166). J. Pharmacol. Exp. Ther. (2003) 307:83-92.
78. THALÉN A, ANDERSSON PH, ANDERSSON PT et al.: Prospects for developing inhaled steroids with extrahepatic metabolism - "soft steroids". In: Inhaled Steroids in Asthma. Optimizing Effects in the Airways. Schleimer RP et al. (FAs), Marcel Dekker, New York (2002):521-537.
79. LAURENT H, GERHARDS E, WIECHERT R: New biologically active pregnan-21-oic acid esters. J. Steroid Biochem. (1975) 6:185-192.
80. PARK K-K, KO D-H, YOU Z, HEIMAN AS, LEE HJ: Synthesis and pharmacological evaluations of new steroidal anti-inflammatory antedrugs: 9α-fluoro-11β,17α, 21-trihydroxy-3, 20-dioxo-pregna-1, 4-diene-16α-carboxylate (FP16CM) and its derivatives. Steroids (2006) 71(1):83-89.
81. RAATIKAINEN MJP, NAPOLITANO CA, DRUZGALA P, DENNIS DM: Electrophysiological effects of a novel, short-acting and potent ester derivative of amiodarone, ATI-2001, in guinea pig isolated heart. J. Pharmacol. Exp. Ther. (1996) 277:1454-1463.
82. MOREY TE, SEUBERT CN, RAATIKAINEN MJP et al.: Structure-activity relationships and electrophysiological effects of short-acting amiodarone homologs in guinea pig isolated heart. J. Pharmacol. Exp. Ther. (2001) 297:260-266.
83. 4 receptor agonist, ATI-7505, in humans. Neurogastroenterol. Motil. (2007) 19(1):30-38.
84. STAFFORD JA, PACOFSKY GJ, COX RF et al.: Identification and structure-activity studies of novel ultrashort-acting benzodiazepine receptor agonists. Bioorg. Med. Chem. Lett. (2002) 12(21):3215-3218.
85. KILPATRICK GJ, TILBROOK GS: Drug development in anaesthesia: industrial perspective. Curr. Opin. Anaesthesiol. (2006) 19(4):385-389.
86. ERICSSON H, THOLANDER B, BJÖRKMAN JA, NORDLANDER M, REGÅRDH CG: Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs. Drug Metab. Dispos. (1999) 27:558-564.
87. NORDLANDER M, SJOQUIST PO, ERICSSON H, RYDEN L: Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc. Drug Rev. (2004) 22(3):227-250.
88. LABAREE DC, REYNOLDS TY, HOCHBERG RB: Estradiol-16α-carboxylic acid esters as locally active estrogens. J. Med. Chem. (2001) 44:1802-1814.
89. LABAREE DC, ZHANG JX, HARRIS HA et al.: Synthesis and evaluation of B-, C-, and D-ring-substituted estradiol carboxylic acid esters as locally active estrogens. J. Med. Chem. (2003) 46:1886-1904.
90. FREYNE EJ, LACRAMPE JF, DEROOSE F et al.: Synthesis and biological evaluation of 1,2,4-triazinylphenylalkylthiazolecarboxylic acid esters as cytokine-inhibiting antedrugs with strong bronchodilating effects in an animal model of asthma. J. Med. Chem. (2005) 48(6):2167-2175.
91. LAZAROVA T, CHEN JS, HAMANN B et al.: Synthesis and biological evaluation of novel cyclosporin A analogues: potential soft drugs for the treatment of autoimmune diseases. J. Med. Chem. (2003) 46:674-676.
92. HERSPERGER R, BUCHHEIT K-H, CAMMISULI S et al.: A locally active antiinflammatory macrolide (MLD987) for inhalation therapy of asthma. J. Med. Chem. (2004) 47(20):4950-4957.